Vaishali Pharma Ltd

Vaishali Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 June 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.

Vaishali Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 04 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Vaishali Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from a risky to an attractive investment grade despite ongoing sector headwinds. The company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a more compelling case relative to its historical averages and peer group, signalling a potential inflection point for investors navigating the Pharmaceuticals & Biotechnology sector.

Vaishali Pharma Ltd has demonstrated a notable shift in its financial trajectory during the quarter ended March 2026, with an improved financial trend score signalling positive momentum despite a decline in net sales. The company’s latest quarterly performance reveals a complex picture of margin pressures and operational challenges, set against a backdrop of a recovering profit after tax and a micro-cap valuation.

Vaishali Pharma Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹92.00 crores, posted a consolidated net profit of ₹0.41 crores in Q4 FY26 (January-March 2026), representing a sharp decline of 68.94% quarter-on-quarter from ₹1.32 crores in Q3 FY26 (October-December 2025). The dramatic profit contraction came despite a modest 9.25% sequential revenue increase to ₹26.93 crores, as the company grappled with negative operating margins and heightened dependence on non-operating income. The stock has been under severe pressure, declining 44.60% over the past year and currently trading at ₹7.03, down 48.27% from its 52-week high of ₹13.59.

Vaishali Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Feb 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 24 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

At Rs 6.85, sellers were still queuing — but there were no buyers willing to take the other side. Vaishali Pharma Ltd locked at its lower circuit of 3.11% on 18 May 2026, with unfilled sell orders and a frozen price.

At Rs 6.82, sellers were still queuing — but there were no buyers willing to take the other side. Vaishali Pharma Ltd locked at its lower circuit of 4.48% on 13 May 2026, with unfilled sell orders and a frozen price.

Vaishali Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Feb 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

At Rs 7.83, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vaishali Pharma Ltd locked at its upper circuit of 3.75% on 8 May 2026, with buyers queuing and no sellers willing to part with shares.

Vaishali Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Feb 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

At Rs 7.55, sellers were still queuing — but there were no buyers willing to take the other side. Vaishali Pharma Ltd locked at its lower circuit of 5% on 30 Apr 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a micro-cap stock with limited liquidity.

At Rs 7.88, sellers were still queuing — but there were no buyers willing to take the other side. Vaishali Pharma Ltd locked at its lower circuit of 4.95% on 24 Apr 2026, with unfilled sell orders and a frozen price, reflecting persistent selling pressure in a micro-cap stock with limited liquidity.

At Rs 9.30, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vaishali Pharma Ltd locked at its upper circuit of 20% on 21 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Vaishali Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Feb 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

At Rs 7.86, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vaishali Pharma Ltd locked at its upper circuit of 9.47% on 17 Apr 2026, with buyers queuing and no sellers willing to part with shares.